Vaxart, Inc.

NASDAQ:VXRT

Biotechnology

Healthcare
$0.53 -1.75%

-$0.01 today

Market cap
$129.30M
Beta
1.09
P/E (TTM)
3.6
EPS (TTM)
$0.15
52W Low $0.26High $0.84

Volume 0.12M

Average 0.41M

VXRT Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Vaxart, Inc.NASDAQ: VXRT

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow dips below year-ago levels

Q1 FY2026 free cash flow of $2.5M (cash outflow) fell 74.3% year over year, behind the +143.9% change in trailing-twelve-month free cash flow.

Context

  • Free cash flow amounted to 3.2% of revenue in FY2025, down 154.7 pp from a year earlier.
  • Free cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -74.3% toward the trailing-twelve-month pace of +143.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.5M-108.2% QoQ
Last fiscal yearDec 2025
$7.57M+116.7% YoY
LTMMar 2026
$14.8M+143.9% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-74.3%——
1 year+116.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
7.57M USD
Year-over-year change
+116.7%

Free Cash Flow vs competitors

How VXRT compares with its peers on the latest reported figures

  • VXRT's LTM Mar 2026 free cash flow of $14.8M is the smallest of the 10 companies compared; the peer median is $50.65M.
  • Its year-over-year change of +143.9% is the 2nd highest of 10, against a peer median of -5.5%.
  • Free cash flow amounts to 5.8% of revenue for VXRT, versus a peer median of 924.5%.
VXRT Competitors Peer median
Free Cash Flow for VXRT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$157.64M +312.0%-28.8%238.3%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$124.96M +0.9%+25.5%1367.7%
IMUXImmunic, Inc.LTM Mar 2026$81.45M -1.7%+9.6%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$75.02M +40.4%+0.9%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$66.29M -5.5%+26.5%—
CBUSCibus, Inc.LTM Mar 2026$50.65M -11.5%+34.8%1181.8%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$42.79M -24.7%-23.9%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$28.67M -7.8%+26.0%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$26.25M -46.9%—667.2%
VXRTVaxart, Inc.LTM Mar 2026$14.8M +143.9%—5.8%
Peer median (excluding VXRT) $50.65M-5.5%+17.5%924.5%

Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(70.47M)(107.76M)(82.47M)(66.95M)16.33M
Depreciation & Amortization4.21M5.81M8.62M8.85M8.58M
Deferred Income Tax3.09M4.09M000
Stock-Based Compensation8.87M13.59M14.13M11.5M8.31M
Change in Working Capital(2.12M)(4.7M)(10.85M)3.26M(22.56M)
Accounts Receivables263K51K(2.99M)(2.75M)(39.38M)
Inventory0(7.11M)000
Accounts Payables1.63M357K(2.44M)5.27M14.64M
Other Working Capital(4.01M)2M(5.42M)742K2.17M
Other Non-Cash Items(3.41M)(5.81M)106K(1.43M)(2.94M)
Operating Cash Flow(59.83M)(94.78M)(70.45M)(44.76M)7.71M
Capital Expenditures(5.16M)(9.6M)(1.87M)(554K)(145K)
Acquisitions (Net)(4.83M)10.81M120K00
Purchases of Investments(44.81M)(55.01M)(27.5M)(54.33M)(19.03M)
Sales of Investments5.7M44.2M73.2M43.5M40M
Other Investing Activities0(10.81M)0(9.95M)(4.2M)
Investing Cash Flow(49.1M)(20.42M)43.95M(21.32M)16.63M
Debt Repayment00000
Common Stock Issued122.21M17.24M15.03M56.78M4.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.59M225K213K(214K)(199K)
Financing Cash Flow125.8M17.46M15.24M56.56M4.24M
Effect of Forex Changes00000
Net Change in Cash16.88M(97.73M)(11.26M)(9.53M)28.59M
Free Cash Flow(64.99M)(104.38M)(72.32M)(45.32M)7.57M

Vaxart, Inc.

NASDAQ:VXRT

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.